Another pan-HDAC inhibitor, MPT0E028, shows a potent HDAC inhibitory effect, that leads to increased apoptosis, and prolongs the overall survival of recipient mice bearing human B-cell lymphoma in a xenograft model (Huang et al., 2015). Here, HDAC9 is linked to B-cell non-Hodgkin lymphoma.